Twist Bioscience Corp
Financial highlights
| Metric | FY September 30, 2025 | FY September 30, 2024 | FY September 30, 2023 | FY September 30, 2022 | FY September 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $376.6M | $313.0M | $245.1M | $203.6M | $132.3M |
| Operating income | -$136.3M | -$220.8M | -$217.2M | -$234.8M | -$152.7M |
| Cost of revenue | $185.6M | $179.6M | $155.4M | $119.3M | $80.6M |
| Cash from operations | -$47.6M | -$64.1M | -$142.5M | -$124.4M | -$112.2M |
| Capital expenditure | $28.0M | $5.1M | $27.8M | $101.9M | $27.1M |
| Free cash flow | -$75.6M | -$69.2M | -$170.3M | -$226.2M | -$139.3M |
| Impairments | $0 | $44.9M | $6.8M | $0 | $0 |
| Total assets | $641.9M | $614.3M | $776.4M | $961.4M | $702.1M |
| Total liabilities | $168.9M | $141.6M | $153.0M | $172.0M | $121.3M |
| Total debt | — | — | — | — | $833,000 |
Shares outstanding 62.3M · Free float 96.9%
Annual filing data through FY ended September 30, 2025; float as of June 27, 2026.